Background: Malignant fibrous histiocytoma (MFH) is a rare bone tumor usually treated like osteosarcoma. Studies on analogies and differences between the two tumors have seldom been reported.
Introduction
Malignant fibrous histiocytoma (MFH) of bone is a rare bone tumor with a high biological aggressiveness and a high metastatic potential. When treated with surgery alone or radiotherapy, the majority of patients develop metastases within two years and die of disseminated disease. The review of literature by Dunham and Wilborn on patients with apparently localized disease at presentation showed that [1] , 21 of the 111 patients (21%) treated with either surgery or radiotherapy survived two years, 16 patients (15%) survived five years and only eight (7%) survived 10 years or more. Recently, similar results have been reported in smaller series [2] [3] [4] [5] [6] , including one from our Institution [3] .
Thus, without chemotherapy the dismal figures for overall and disease-free survival are similar to those of osteosarcoma. Several studies have reported that neoadjuvant chemotherapy improves the cure rate from 10%-15% to 60%-70% for patients with high-grade osteosarcoma of the extremities, and reduces the need for amputation from 90%-100% to 10%-30% [7] [8] [9] [10] [11] [12] , while there are only three small series [4, 13, 14] , including, respectively, nine, nine and 22 patients, that prove neoadjuvant chemotherapy effective also in MFH of bone. In these studies neoadjuvant chemotherapy was given in the same regimens as those used for osteosarcoma at the authors' institutions. However, whether MFH of bone and osteosarcoma, when treated with the same neoadjuvant chemotherapy regimen, are really identical in terms of histologic response to chemotherapy, and local and systemic control, has not yet been investigated.
The purpose of this paper is to compare the results obtained in 51 patients with MFH and in 390 patients with osteosarcoma of the extremities treated with the same neoadjuvant chemotherapy regimen at our Institution between 1983 and 1994. The previously reported results on 283 of these patients [7, 8, 15] , are here updated.
Patients and methods

Patient selection and pathology
This report considered only the cases of MFH and osteosarcoma which fulfilled the following criteria: a) typical histologic and radiologic features of high-grade MFH or of primary high-grade central osteosarcoma; b) tumor located in the extremities; c) age under 60 for patients with MFH and under 40 for patients with osteosarcoma; d) no previous treatments; e) absence of detectable metastases at the time of diagnosis; and 0 no contraindication to chemotherapy treatment.
Of the 130 newly diagnosed cases of MFH of bone and of the 760 cases of osteosarcoma seen at the Rizzoli Institute between March 1983 and December 1994, 65 MFH patients and 538 osteosarcoma patients met the specified criteria. Of these patients 164 (148 with osteosarcoma and 14 with MFH) were excluded because the two tumors in the same years were not treated with the same chemotherapy regimen. This study therefore reports on 441 patients (51 MFH and 390 osteosarcoma) treated with the same neoadjuvant chemotherapy regimens. The characteristics of these 441 patients are reported in Table 1. MFH and osteosarcoma were diagnosed by clinical and radiographic findings and confirmed on histologic slides of the tumor tissue obtained from open biopsies as well as from resected specimens.
MFH of bone was defined according to the following criteria: a clear pleomorphic sarcoma composed of a mixture of fibroblast-like and histiocyte-like cells arising in the bone, a storiform arrangement of spindle-shaped cells, malignant giant cells, foam cells, anaplastic stromal cells, and abnormal mitosis. Tumors with osteoid or chondroid formation were not included even if they otherwise met the criteria. The tumors were graded according to Broders' classification. All cases considered were high-grade tumors (grades III-IV). Three pathologists reviewed the slides and all agreed on the diagnosis and grade of malignancy. Three of the 51 MFH occurred in bones affected by preexisting diseases (two bone infarcts and one chondroma).
Preoperative evaluation and preoperatlve chemotherapy
Complete histories were taken on all patients, and they underwent thorough physical examinations and several chemical laboratory tests. The primary tumor was evaluated on plain radiograms, Technetium 99-MDP bone scans, angiograms, CT scans and, in the more recent cases, MRI. All of these examinations were repeated before surgery. Bone metastases were excluded by total body scan, and chest radiographs and CT scans were used to investigate the lungs.
Preoperative chemotherapy was administered according to three different, successively activated, regimens, as detailed in Figure 1 MTX was always given in high doses, which, however, were different in the three regimens (7.5 g/m 2 in regimen 1; 8 g/m 2 in regimen 2; and 12 g/m 2 in regimen 3). The doses and the infusion times of CDP (120 mg/m 2 in 72 hours) and ADM (60 mg in 8 hours) were the same for all three regimens. In the first two studies CDP was delivered intrarterially, while in the third it was given either intrarterially or intravenously. IFO (2 g/m 2 /day for five consecutive days) was used preoperatively only in the last study.
Surgery
Surgery was performed three weeks after the last cycle of chemotherapy and after a complete restaging of the lesion. The type of surgery (amputation or limb salvage) and the type of reconstruction (prosthesis, bone graft, rod/plate and cement, vascularized fibula) were chosen according to tumor location and extent, patient age, life-style, and preferences. However, a prerequisite for conservative surgery was preoperative-staging evidence that it would be possible to achieve wide surgical margins, i.e., complete removal of the tumor surrounded by healthy tissue with no intraoperative contamination.
Pathology examination
In all cases the surgeon and the pathologist reviewed the gross specimen to determine surgical margins that were classified according to Enneking's classification [16] as radical, wide, marginal or intralesional. The percentage of tumor necrosis was histologically evaluated by a method previously reported [17] . The response to preoperative chemotherapy was rated 'good' if tumor necrosis was equal to or greater than 90%, and 'poor' if it was less than 90%. Within the group of good responders there was a subgroup of patients with total response (no tumor cells).
Postoperative chemotherapy and follow-up
Postoperative chemotherapy was started three to 21 days after surgery ( Figure 2 ). In the first two regimens patients received different postoperative treatments according to the histologic response. In the first study salvage chemotherapy was ADM and three drugs that were not used preoperatively [bleomycin, cyclophosphamide, actinomycin D (BCD)]. In the second study IFO and VP-16 were added to the three drugs (MTX, CDP and ADM) used preoperatively. In regimen 3 postoperative treatment was the same for all patients, but patients who had a poor necrosis received an extra cycle.
During postoperative chemotherapy, in addition to clinical evaluations, patients were followed every two months with radiographs of the chest and operated limb. Additional investigations were performed only in case of clinical and/or radiographic suspicion of relapse. After completion of chemotherapy, all patients were followed in the outpatient clinic with the above-cited radiographs every two months for two years, every three months the third year and subsequently every six months.
Calculation of dose intensity
Chemotherapy dose intensity was calculated by dividing the amount of drugs given (mg/m 2 ) by the length (in weeks) of treatment. According to the method described by Hryniuk and Bush [18] dose intensity was calculated by combining the values of each drug in a single value. The actual dose intensity received by patients was expressed as the percentage of the projected dose intensity according to the regimen (i.e., the dose intensity of a patient who had had no dose reduction or delays in treatment). 
Statistical considerations
The major endpoints of the study were the histological response to primary chemotherapy and the event-free survival (EFS). Overall survival was also evaluated, but the relative data should be considered with caution. After relapse, several patients preferred to move to other institutions, so the post-relapse treatment was not homogeneous. EFS was calculated from the day of the start of primary chemotherapy until the first adverse event or to the most recent follow-up. Adverse events included the development of recurrent tumor in any site or death in remission of chemotherapy-related causes. Patients who died of unrelated causes were excluded. Results were updated in December 1996.
The cumulative probability curves of disease-free and overall survival as a function of time were calculated according to the actuarial method [19] and the curves for the two groups of patients (MFH vs. osteosarcoma) were compared univariately by a log-rank test [20] .
Results
Clinical and radiologic response to preoperative chemotherapy
After preoperative chemotherapy, a clinical and radiographic tumor response was observed in 39 patients (76%) with MFH and in 350 patients (90%) with osteosarcoma, while there were no significant changes in 48 cases. The remaining four patients, all in the osteosarcoma group, had tumor progression during chemotherapy.
Most of the 389 patients who responded to chemotherapy had a reduction or complete remission of pain (if present), a decrease, in most instances to normal, of the serum alkaline phosphatase levels (if elevated), a reduction in tumor size, and a decreased vascularity on the angiograms. An increased radiologic density of the lesion was generally observed in patients with osteosarcoma.
Surgery and histologic response topreoperative chemotherapy
Three-hundred seventy-three patients (84.5%) were surgically treated by limb salvage, 15 by rotation plasty (3.5%) and 53 by amputation (12%). The percentages of limb salvage procedures performed were 92% for patients with MFH and 84% for osteosarcoma (Table 2) , with no differences among the three regimens. Although limb salvage was planned only when adequate surgical margins (radical or wide) were feasible, 48 (11%) patients (five in the MFH group and 43 in the osteosarcoma group) had inadequate (marginal or intralesional) margins.
The histologic response to chemotherapy determined by the percentage of necrosis was 'good' in 276 patients (63%) and 'poor' in 165 (37%). In 77 cases (17%) a total necrosis was observed.
Good histologic response was significantly higher in patients treated with regimens 2 and 3 which preoperatively used three and four drugs, respectively, compared to patients treated with regimen 1 in which only two drugs were used before surgery (73% vs. 50%, P = 0.00001; and 68% vs. 50%, P = 0.0002). On the other hand, no differences were observed between patients treated with regimens 2 and 3 (73% vs. 68%, P -NS).
The same results were achieved when, instead of good response, only the rate of total necrosis was considered (4% in regimen 1 vs. 21.5% in regimen 2, P -0.0001, and 32.5% in regimen 3, P -0.00001).
Regardless of the chemotherapy regimen used, the rate of good histologic response as well as the rate of total necrosis were significantly higher in patients with osteosarcoma than in patients with MFH ( 262 of 390 -67% vs. 14 of 51 -27%; P = 0.00001, and two of 51 -4% vs. 75 of 390 -19%; P = 0.01) ( Table 2) .
Disease-free survival and relapse
At an average follow-up of 7.5 years (2-13 years) 288 patients (65%) remained continuously free of disease, 148 patients (34%) relapsed and five (1%), all in the osteosarcoma group, died of chemotherapy-related toxicity (Table 3) . The rate of disease-free survival was the same in the MFH and osteosarcoma groups (67% vs. 65%). The results of the three different regimens were comparable in the MFH group, while in patients with osteosarcoma the results of the second and third regimens were significantly better than those of regimen 1 (Table 3) .
For the histologic response to chemotherapy there was a correlation between the grade of chemotherapyinduced necrosis and the disease-free survival rate, which was significantly higher in the good than in the poor responders (203 of 271 -75% vs. 85 of 165 -52%, P = 0.00001) ( Table 4) . This difference was significant for both MFH (93% vs. 57%, P -0.04) and osteosarcoma patients (74% vs. 50%, P -0.00001). Patients with a good response fared better in the MFH group than those in the osteosarcoma group (93% vs. 74%), whereas for poor responders no differences in disease-free survival were observed for the two tumors (57% vs. 50%) ( Table 4) .
Local recurrences
There were 18 local recurrences, two in the 51 patients (4%) with MFH and 16 in the 390 patients (4%) with osteosarcoma. All local recurrences were associated with metastases (four before and 14 after the local relapse). All but one of these patients had had a limb salvage and the surgical margins were adequate in five and inadequate in 13. The histological response was good in seven and poor in 11. It is important to note that three patients who developed local recurrences (all in the osteosarcoma group) had had a total necrosis. The rate of local recurrence according to type of surgery was one of 68 (1.5%) for patients amputated or treated with a rotation plasty, and 17 of 373 (4.5%) for patients treated with limb salvage. This difference was not statistically significant.
According to surgical margins the rate of local recurrence was significantly higher in patients with inadequate margins than in those with adequate surgical margins (13 of 48 -27% vs. five of 393 -1.3%, P = 0.00001). For histologic response the local recurrences were seven out of 276 (2.5%) for good-responder patients and 11 out of 165 (6.7%) for poor responders.
This difference was close to statistical significance (P = 0.06).
One hundred forty-eight patients relapsed with metastases, which in 126 (85%) was initially located in the lung and in 20 patients (13.5%) in bone. In the remaining two patients the first metastases were, respectively, in the heart and kidney. The percentage of patients in whom the first metastases were located in the bones was significantly higher in the MFH than in the osteosarcoma group (seven of 17 -41% vs. 13 of 131 -9.9%, P = 0.001).
The average time to relapse was 18.4 months for the MFH group and 21.9 months for the osteosarcoma group.
Post-relapse outcome
Five of the 18 patients who had local recurrences were treated with palliative radiotherapy. Four of these five patients already had disseminated metastatic disease at the time of the local recurrence. Of the remaining 13, all initially treated with limb salvage, four underwent another resection and nine amputation. All but one of these 18 patients died of tumor six to 28 months after the recurrence. The remaining patient is alive and diseasefree 20 months after limb salvage for the recurrence.
The 131 patients who relapsed only for metastases were generally treated, in our hospital or in other institutions, with metastasectomy, sometimes reiterated, and followed in most cases by further chemotherapy with different drugs. Of these patients, 88 died of the tumor, nine are alive with uncontrolled disease and 34 are alive and free of disease three months to 12 years (median 43 mos) after the last treatment. The percentage of patients presently alive and disease-free after relapse was higher in the osteosarcoma group (34 of 131 -26%) than in the MFH group (one of 17 -6%). This difference, however, was not statistically significant.
Chemotherapy toxicity
Compliance with the chemotherapy regimens was significantly better for patients in the osteosarcoma group than for the MFH patients. In the two groups the mean dose intensity was 92% versus 84% of the projected value. In particular, while in the osteosarcoma group 321 of 390 patients (82%) received chemotherapy with an actual dose intensity of more than 85% of the projected value, in the MFH group only 26 of 51 patients (51%) had an equivalent dose intensity (P -0.00001). It was assumed that the worse compliance with the regimens observed for the MFH group was due to the patients' older age.
A grade 4 hematologic toxicity followed 19.7% of all chemotherapy cycles, and in 8.9% of these cycles it was necessary to hospitalize patients for treatment due to clinical symptoms such as fever during the granulocytic phase or hemorrhages. The rate of grade 4 toxicities (30% vs. 18.3%, P = 0.00001) as well the need for hospitalization (13.9% vs. 8.3%, P = 0.0001) were both significantly higher in the MFH group than in the osteosarcoma group.
One osteosarcoma patient died of sepsis during the myelodepression phase.
The major extrahematologic toxicity was a severe ADM cardiotoxicity in 13 cases, which led to four deaths and two heart transplants. Eleven of the 13 ADM cardiotoxicities were seen in the osteosarcoma group.
A delayed elimination of MTX was observed in 3.9% of all cycles. Delayed MTX elimination was higher in the MFH group than in the osteosarcoma group (5.8% vs. 3.7%, P 0.03). Moreover, it was higher after the cycles performed in 39 patients aged over 30 than after the cycles performed in 402 patients under 30 years of age (6.0% vs. 3.8%, P = 0.04).
Discussion
MFH of bone is a relatively rare tumor whose biological aggressiveness and tendency to metastatize are no different from those of osteosarcoma [1] [2] [3] [4] [5] . While for osteosarcoma several large series report that neoadjuvant chemotherapy improves the cure rate and reduces the need for amputation [7, 8, [10] [11] [12] , for MFH, apart from some anecdotal reports [21] [22] [23] [24] , only three small series, including a total of 40 patients, report the effectiveness of neoadjuvant treatment [4, 13, 25] .
The results of the present study on 51 patients with MFH of bone treated over 12 years with the same regimens of neoadjuvant chemotherapy used for 390 contemporary cases of osteosarcoma, confirm that neoadjuvant chemotherapy is as effective in high-grade MFH of bone as in high-grade osteosarcoma. Disease-free survival (67% vs. 65%) was the same for the two tumors, although chemotherapy dose intensity was lower in the MFH group, probably due to these patients' older age. Furthermore, the study revealed that, as in the case of osteosarcoma, MFH of bone also showed a significant correlation between histologic response to chemotherapy and prognosis. The disease-free survival was 93% for good-responder patients and 57% for poor responders {P = 0.04). This correlation seems to indicate that also in MFH there is a similar chemosensitivity between the primary tumor and micrometastases, which are assumed to be present in over 80% of MFH patients with apparently localized disease at diagnosis.
In both tumors, in most patients it was possible to avoid amputation, and limb salvage was safe. The rate of local recurrences for resected patients was 4.5% with no differences between patients with MFH and those with osteosarcoma. However, it is important to stress that in patients with inadequate surgical margins, the 25% rate of local recurrence was very high. For this reason, in these two tumors a limb salvage procedure should be planned only when preoperative staging assures the feasiblity of adequate surgical margins. Moreover, a careful histopathological study of the surgical margin should always be performed, and in view of the high risk of local recurrence and thus the poor prognosis, when margins are inadequate an amputation should be considered, especially after poor necrosis.
The tumors showed two major differences: the pattern of relapse and the chemosensitivity to preoperative chemotherapy. This could be explained by the difference in biological behavior of the two tumors. On the other hand, an unbalanced distribution of prognostic factors such as age, tumor volume, SAP and LDH levels (Table 1) could have influenced these findings.
In MFH the percentage of patients in whom bone was the first site of metastasis was significantly higher than the one for osteosarcoma (35% vs. 8.4%, P -0.04).
The two tumors also have different chemosensitivities. Comparison of the results of 51 patients with MFH of the extremities to those of 390 patients with highgrade osteosarcoma of the extremities treated during the same period with the same neoadjuvant regimens showed that the histologic response of MFH to primary chemotherapy was less than the one of osteosarcoma. In MFH the rate of good response (27% vs. 67%, P = 0.00001) as well as the rate of total response (4% vs. 19%, P = 0.01) were both significantly lower than in osteosarcoma. The statistically significant difference is maintained within the individual regimens, despite the small number of MFH in each group.
A good histologic response to primary chemotherapy in patients with MFH of bone is infrequent, but it seems to be associated with a very good outcome. In this study, 93% of the MFH patients with good histologic response were continuously disease-free, with a mean follow-up of 7.5 years. This rate was higher than that achieved in the osteosarcoma patients with good histologic response (DFS: 74%). This difference was not statistically significant, probably due to the small number of good responders in the MFH group.
This different chemosensitivity could indicate a different biology of the two tumors, confirming that MFH is really a distinct clinicopathologic entity, and not just an undifferentiated osteogenic bone sarcoma.
The observation that, as opposed to osteosarcoma, in MFH a large number of patients have poor necrosis after preoperative chemotherapy deserves a comment on the need to use preoperative treatment in MFH. In osteosarcoma of the extremities preoperative neoadjuvant chemotherapy has been used in almost all recent studies. However, a benefit in survival with neoadjuvant chemotherapy, independently of its role in enhancing limb-sparing surgery, remain to be proven. Contemporary trials, such as the MIOS study [26] , which used preoperative chemotherapy with or without customizing postoperative treatment, have not had better overall results than those achieved with immediate surgery and postoperative adjuvant chemotherapy. Advocated at the end of the 1970s [27] , neoadjuvant treatment in osteosarcoma seemed to offer the four following advantages: a) enhancement of limb sparing surgery; b) provision of a window of time during which customized endoprosthetic devices could be made; c) delivery of early systemic treatment against micrometasases; d) tailoring of postoperative chemotherapy based on the primary tumor response. Today, with the possible exception of the first, these advantages are no longer true. Chemotherapy is presently started, with no high risk, a few days after surgery. The new surgical techniques of reconstruction as well as the new prostheses [28] no longer require waiting for a custom-made device; and pre-and postoperative treatment are usually performed using all four of the drugs effective in osteosarcoma (MTX, CDP, ADM, IFO) regardless of the histologic response to preoperative treatment [9, 29] . Compared to adjuvant treatment, preoperative chemotherapy could carry some risks. When the primary tumor is non-responsive delayed surgery could increase the risk of systemic spread of the drug-resistant tumor cells and/or increase the chance of selecting drug-resistant clones which may then metastasize.
In the present study about 3/4 of the osteosarcoma patients had good histologic response to preoperative treatment, compared to only 1/4 of the MFH patients. It is therefore possible that in this tumor immediate surgery followed by adjuvant chemotherapy would be more appropriate.
